Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
Yu XueJiankang HuDongzhou LiuJingyang LiHuaxiang WuChunyu TanLie DaiLingyun SunZhijun LiZhengyu XiaoCibo HuangYan YanFei JiRong ChenHejian ZouPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
ClinicalTrials.gov identifier: NCT04285229.